Synthetic hydrogel carriers for muscle repair

A kit comprising:

• a) a syringe comprising a hydrogel precursor;
• b) a mixing vessel comprising a crosslinking agent;
• and
• c) an injection needle;
• wherein either of the syringe or mixing vessel comprise at least one pro-myogenic agent;
• and
• wherein the syringe is in fluid communication with the mixing vessel and injection needle, in which the mixing vessel is disposed between the needle and syringe;
• wherein the hydrogel precursor has the general formula:
• C represents a core, Q represents a linker, Z represents an adhesion peptide, Q1 represents a functional group capable of reacting with cysteine, and the sum of a1+b1 together is an integer of 3 or greater
• wherein the adhesion peptide comprises the sequence GRGDSPC (SEQ ID NO:
• 1), CRGDS (SEQ ID NO:
• 2), CRGDSP (SEQ ID NO:
• 3), CPHSRN (SEQ ID NO:
• 4), CGWGGRGDSP (SEQ ID NO:
• 5), CGGSIDQVEPYSSTAQ (SEQ ID NO:
• 6), CGGRNIAEIIKDI (SEQ ID NO:
• 7), CGGDITYVRLKF (SEQ ID NO:
• 8), CGGDITVTLNRL (SEQ ID NO:
• 9), CGGRYVVLPR (SEQ ID NO:
• 10), CGGKAFDITYVRLKF (SEQ ID NO:
• 11), CGGEGYGEGYIGSR (SEQ ID NO:
• 12), CGGATLQLQEGRLHFXFDLGKGR, wherein X=Nle (SEQ ID NO:
• 13), CGGSYWYRIEASRTG (SEQ ID NO:
• 14), CGGGEFYFDLRLKGDKY (SEQ ID NO:
• 15), CKGGNGEPRGDTYRAY (SEQ ID NO:
• 16), CKGGPQVTRGDVFTMP (SEQ ID NO:
• 17), CGGNRWHSIYITRFG (SEQ ID NO:
• 18), CGGASIKVAVSADR (SEQ ID NO:
• 19), CGGTTVKYIFR (SEQ ID NO:
• 20), CGGSIKIRGTYS (SEQ ID NO:
• 21), CGGSINNNR (SEQ ID NO:
• 22), CGGSDPGYIGSR (SEQ ID NO:
• 23), CYIGSR (SEQ ID NO:
• 24), CGGTPGPQGIAGQGVV (SEQ ID NO:
• 25), CGGTPGPQGIAGQRVV (SEQ ID NO:
• 26), CGGMNYYSNS (SEQ ID NO:
• 27), CGGKKQRFRHRNRKG (SEQ ID NO:
• 28), CRGDGGGGGGGGGGGGGPHSRN (SEQ ID NO:
• 29), CPHSRNSGSGSGSGSGRGD (SEQ ID NO:
• 30), Acetylated-GCYGRGDSPG (SEQ ID NO:
• 31), ((GPP) 5GPC) (SEQ ID NO:
• 32), CRDGS (SEQ ID NO:
• 33), cyclic RGD {Fd}C (SEQ ID NO:
• 34), CGGRKRLQVQLSIRT (SEQ ID NO:
• 35), CIKVAV (SEQ ID NO:
• 36), CGGAASIKVAVSADR (SEQ ID NO:
• 37), CGGKRTGQYKL (SEQ ID NO:
• 38), CGGTYRSRKY (SEQ ID NO:
• 39), CGGYGGGP (GPP) 5GFOGERPP (GPP) 4GPC (SEQ ID NO:
• 40), CGGKRTGQYKLGSKTGPGQK (SEQ ID NO:
• 41), QAKHKQRKRLKSSC (SEQ ID NO:
• 42), SPKHHSQRARKKKNKNC (SEQ ID NO:
• 43), CGGXBBXBX, wherein B=basic residue and X=hydropathic residue (SEQ ID NO:
• 44), and CGGXBBBXXBX, wherein B=basic residue and X=hydropathic residue (SEQ ID NO:
• 45), or a combination thereof;
• wherein the crosslinking agent comprises a peptide having the sequence GCRDGPQG↓WGQDRCG (SEQ ID NO:
• 46), GCRDGPQG↓IAGQDRCG (SEQ ID NO:
• 47), GCRDVPMS↓MRGGDRCG (SEQ ID NO:
• 48), GCRDIPVS↓LRSGDRCG (SEQ ID NO:
• 49), GCRDRPFS↓MIMGDRCG (SEQ ID NO:
• 50), GCRDVPLS↓LTMGDRCG (SEQ ID NO:
• 51), GCRDVPLS↓LYSGDRCG (SEQ ID NO:
• 52), GCRDIPES↓LRAGDRCG (SEQ ID NO:
• 53), GCRDSGESPAY↓YTADRCG (SEQ ID NO:
• 54), GCRDGGYAE↓LRMGGDRCG (SEQ ID NO:
• 55), GCRDGGPLG↓LYAGGDRCG (SEQ ID NO:
• 56), or GCRDGPLG↓LWARDRCG SEQ ID NO:
• 57), 1,4-dithiothreitol poly (ethylene glycol) dithiol, or a combination thereof;
• wherein the pro-myogenic agent comprises muscle stem cells, muscle satellite cells, a pro-myogenic protein, or a combination thereof;
• and
• wherein C represents a group having the formula:
• wherein q is from 1-6.